Inflammatory Breast Cancer Research 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.HER2/positive and HER2/low in inflammatory breast cancer recurrence
This study aimed to investigate the impact of HER2-low on the risk of recurrence in individuals with inflammatory breast cancer (IBC). 60 females with HER2-low and HER2-positive IBC underwent surgery between July 2020 and July 2022. Patients were divided into three groups of 20 patients: (1) HRplus/HER2-, (2) HRplus/HERplus, and (3) HR-/HER2plus. All patients underwent chemotherapy in adjuvant mode, following this scheme: TCH=docetaxel and carboplatin plus Herceptin (HER2 target - 4 mg/kg as the loading dose and 6 mg/kg as subsequent doses throughout every 21 days, entire 52 weeks of Herceptin therapy). HRplus/HERplus grou...
Source: Journal of Medicine and Life - February 10, 2023 Category: General Medicine Authors: Oleksii Volodimirovich Movchan Irina Yuriivna Bagmut Andriy Fedorovich Shipko Ivan Ivanovich Smolanka Senior Michael Ivanovich Sheremet Igor Leonidovich Kolisnyk Oleksandr Vasyliovych Bagmut Andriy Oleksandrovich Lyashenko Anton Dmitrovich Loboda Oksana M Source Type: research
Aspirin Use Is Associated With Improved Outcomes in Inflammatory Breast Cancer Patients
CONCLUSION: ASA use during remission was associated with significantly improved OS and DMFS in patients with IBC. These results suggest that ASA may provide survival benefits to patients with IBC. Prospective clinical trials of ASA use in patients with high-risk IBC in remission should be considered.PMID:36762783 | DOI:10.4048/jbc.2023.26.e3 (Source: Journal of Breast Cancer)
Source: Journal of Breast Cancer - February 10, 2023 Category: Cancer & Oncology Authors: Christopher Johns Allen Yen Asal Rahimi Yu-Lun Liu Ann Marilyn Leitch Ann Spangler Prasanna Alluri Chika Nwachukwu Rachel Wooldridge Deborah Farr D W Nathan Kim Source Type: research
HER2/positive and HER2/low in inflammatory breast cancer recurrence
This study aimed to investigate the impact of HER2-low on the risk of recurrence in individuals with inflammatory breast cancer (IBC). 60 females with HER2-low and HER2-positive IBC underwent surgery between July 2020 and July 2022. Patients were divided into three groups of 20 patients: (1) HRplus/HER2-, (2) HRplus/HERplus, and (3) HR-/HER2plus. All patients underwent chemotherapy in adjuvant mode, following this scheme: TCH=docetaxel and carboplatin plus Herceptin (HER2 target - 4 mg/kg as the loading dose and 6 mg/kg as subsequent doses throughout every 21 days, entire 52 weeks of Herceptin therapy). HRplus/HERplus grou...
Source: Journal of Medicine and Life - February 10, 2023 Category: General Medicine Authors: Oleksii Volodimirovich Movchan Irina Yuriivna Bagmut Andriy Fedorovich Shipko Ivan Ivanovich Smolanka Senior Michael Ivanovich Sheremet Igor Leonidovich Kolisnyk Oleksandr Vasyliovych Bagmut Andriy Oleksandrovich Lyashenko Anton Dmitrovich Loboda Oksana M Source Type: research
Aspirin Use Is Associated With Improved Outcomes in Inflammatory Breast Cancer Patients
CONCLUSION: ASA use during remission was associated with significantly improved OS and DMFS in patients with IBC. These results suggest that ASA may provide survival benefits to patients with IBC. Prospective clinical trials of ASA use in patients with high-risk IBC in remission should be considered.PMID:36762783 | DOI:10.4048/jbc.2023.26.e3 (Source: Journal of Breast Cancer)
Source: Journal of Breast Cancer - February 10, 2023 Category: Cancer & Oncology Authors: Christopher Johns Allen Yen Asal Rahimi Yu-Lun Liu Ann Marilyn Leitch Ann Spangler Prasanna Alluri Chika Nwachukwu Rachel Wooldridge Deborah Farr D W Nathan Kim Source Type: research
HER2/positive and HER2/low in inflammatory breast cancer recurrence
This study aimed to investigate the impact of HER2-low on the risk of recurrence in individuals with inflammatory breast cancer (IBC). 60 females with HER2-low and HER2-positive IBC underwent surgery between July 2020 and July 2022. Patients were divided into three groups of 20 patients: (1) HRplus/HER2-, (2) HRplus/HERplus, and (3) HR-/HER2plus. All patients underwent chemotherapy in adjuvant mode, following this scheme: TCH=docetaxel and carboplatin plus Herceptin (HER2 target - 4 mg/kg as the loading dose and 6 mg/kg as subsequent doses throughout every 21 days, entire 52 weeks of Herceptin therapy). HRplus/HERplus grou...
Source: Journal of Medicine and Life - February 10, 2023 Category: General Medicine Authors: Oleksii Volodimirovich Movchan Irina Yuriivna Bagmut Andriy Fedorovich Shipko Ivan Ivanovich Smolanka Senior Michael Ivanovich Sheremet Igor Leonidovich Kolisnyk Oleksandr Vasyliovych Bagmut Andriy Oleksandrovich Lyashenko Anton Dmitrovich Loboda Oksana M Source Type: research
Aspirin Use Is Associated With Improved Outcomes in Inflammatory Breast Cancer Patients
CONCLUSION: ASA use during remission was associated with significantly improved OS and DMFS in patients with IBC. These results suggest that ASA may provide survival benefits to patients with IBC. Prospective clinical trials of ASA use in patients with high-risk IBC in remission should be considered.PMID:36762783 | DOI:10.4048/jbc.2023.26.e3 (Source: Journal of Breast Cancer)
Source: Journal of Breast Cancer - February 10, 2023 Category: Cancer & Oncology Authors: Christopher Johns Allen Yen Asal Rahimi Yu-Lun Liu Ann Marilyn Leitch Ann Spangler Prasanna Alluri Chika Nwachukwu Rachel Wooldridge Deborah Farr D W Nathan Kim Source Type: research
HER2/positive and HER2/low in inflammatory breast cancer recurrence
This study aimed to investigate the impact of HER2-low on the risk of recurrence in individuals with inflammatory breast cancer (IBC). 60 females with HER2-low and HER2-positive IBC underwent surgery between July 2020 and July 2022. Patients were divided into three groups of 20 patients: (1) HRplus/HER2-, (2) HRplus/HERplus, and (3) HR-/HER2plus. All patients underwent chemotherapy in adjuvant mode, following this scheme: TCH=docetaxel and carboplatin plus Herceptin (HER2 target - 4 mg/kg as the loading dose and 6 mg/kg as subsequent doses throughout every 21 days, entire 52 weeks of Herceptin therapy). HRplus/HERplus grou...
Source: Journal of Medicine and Life - February 10, 2023 Category: General Medicine Authors: Oleksii Volodimirovich Movchan Irina Yuriivna Bagmut Andriy Fedorovich Shipko Ivan Ivanovich Smolanka Senior Michael Ivanovich Sheremet Igor Leonidovich Kolisnyk Oleksandr Vasyliovych Bagmut Andriy Oleksandrovich Lyashenko Anton Dmitrovich Loboda Oksana M Source Type: research
Aspirin Use Is Associated With Improved Outcomes in Inflammatory Breast Cancer Patients
CONCLUSION: ASA use during remission was associated with significantly improved OS and DMFS in patients with IBC. These results suggest that ASA may provide survival benefits to patients with IBC. Prospective clinical trials of ASA use in patients with high-risk IBC in remission should be considered.PMID:36762783 | DOI:10.4048/jbc.2023.26.e3 (Source: Journal of Breast Cancer)
Source: Journal of Breast Cancer - February 10, 2023 Category: Cancer & Oncology Authors: Christopher Johns Allen Yen Asal Rahimi Yu-Lun Liu Ann Marilyn Leitch Ann Spangler Prasanna Alluri Chika Nwachukwu Rachel Wooldridge Deborah Farr D W Nathan Kim Source Type: research
HER2/positive and HER2/low in inflammatory breast cancer recurrence
This study aimed to investigate the impact of HER2-low on the risk of recurrence in individuals with inflammatory breast cancer (IBC). 60 females with HER2-low and HER2-positive IBC underwent surgery between July 2020 and July 2022. Patients were divided into three groups of 20 patients: (1) HRplus/HER2-, (2) HRplus/HERplus, and (3) HR-/HER2plus. All patients underwent chemotherapy in adjuvant mode, following this scheme: TCH=docetaxel and carboplatin plus Herceptin (HER2 target - 4 mg/kg as the loading dose and 6 mg/kg as subsequent doses throughout every 21 days, entire 52 weeks of Herceptin therapy). HRplus/HERplus grou...
Source: Journal of Medicine and Life - February 10, 2023 Category: General Medicine Authors: Oleksii Volodimirovich Movchan Irina Yuriivna Bagmut Andriy Fedorovich Shipko Ivan Ivanovich Smolanka Senior Michael Ivanovich Sheremet Igor Leonidovich Kolisnyk Oleksandr Vasyliovych Bagmut Andriy Oleksandrovich Lyashenko Anton Dmitrovich Loboda Oksana M Source Type: research
Aspirin Use Is Associated With Improved Outcomes in Inflammatory Breast Cancer Patients
CONCLUSION: ASA use during remission was associated with significantly improved OS and DMFS in patients with IBC. These results suggest that ASA may provide survival benefits to patients with IBC. Prospective clinical trials of ASA use in patients with high-risk IBC in remission should be considered.PMID:36762783 | DOI:10.4048/jbc.2023.26.e3 (Source: Journal of Breast Cancer)
Source: Journal of Breast Cancer - February 10, 2023 Category: Cancer & Oncology Authors: Christopher Johns Allen Yen Asal Rahimi Yu-Lun Liu Ann Marilyn Leitch Ann Spangler Prasanna Alluri Chika Nwachukwu Rachel Wooldridge Deborah Farr D W Nathan Kim Source Type: research
HER2/positive and HER2/low in inflammatory breast cancer recurrence
This study aimed to investigate the impact of HER2-low on the risk of recurrence in individuals with inflammatory breast cancer (IBC). 60 females with HER2-low and HER2-positive IBC underwent surgery between July 2020 and July 2022. Patients were divided into three groups of 20 patients: (1) HRplus/HER2-, (2) HRplus/HERplus, and (3) HR-/HER2plus. All patients underwent chemotherapy in adjuvant mode, following this scheme: TCH=docetaxel and carboplatin plus Herceptin (HER2 target - 4 mg/kg as the loading dose and 6 mg/kg as subsequent doses throughout every 21 days, entire 52 weeks of Herceptin therapy). HRplus/HERplus grou...
Source: Journal of Medicine and Life - February 10, 2023 Category: General Medicine Authors: Oleksii Volodimirovich Movchan Irina Yuriivna Bagmut Andriy Fedorovich Shipko Ivan Ivanovich Smolanka Senior Michael Ivanovich Sheremet Igor Leonidovich Kolisnyk Oleksandr Vasyliovych Bagmut Andriy Oleksandrovich Lyashenko Anton Dmitrovich Loboda Oksana M Source Type: research
Aspirin Use Is Associated With Improved Outcomes in Inflammatory Breast Cancer Patients
CONCLUSION: ASA use during remission was associated with significantly improved OS and DMFS in patients with IBC. These results suggest that ASA may provide survival benefits to patients with IBC. Prospective clinical trials of ASA use in patients with high-risk IBC in remission should be considered.PMID:36762783 | DOI:10.4048/jbc.2023.26.e3 (Source: Journal of Breast Cancer)
Source: Journal of Breast Cancer - February 10, 2023 Category: Cancer & Oncology Authors: Christopher Johns Allen Yen Asal Rahimi Yu-Lun Liu Ann Marilyn Leitch Ann Spangler Prasanna Alluri Chika Nwachukwu Rachel Wooldridge Deborah Farr D W Nathan Kim Source Type: research
HER2/positive and HER2/low in inflammatory breast cancer recurrence
This study aimed to investigate the impact of HER2-low on the risk of recurrence in individuals with inflammatory breast cancer (IBC). 60 females with HER2-low and HER2-positive IBC underwent surgery between July 2020 and July 2022. Patients were divided into three groups of 20 patients: (1) HRplus/HER2-, (2) HRplus/HERplus, and (3) HR-/HER2plus. All patients underwent chemotherapy in adjuvant mode, following this scheme: TCH=docetaxel and carboplatin plus Herceptin (HER2 target - 4 mg/kg as the loading dose and 6 mg/kg as subsequent doses throughout every 21 days, entire 52 weeks of Herceptin therapy). HRplus/HERplus grou...
Source: Journal of Medicine and Life - February 10, 2023 Category: General Medicine Authors: Oleksii Volodimirovich Movchan Irina Yuriivna Bagmut Andriy Fedorovich Shipko Ivan Ivanovich Smolanka Senior Michael Ivanovich Sheremet Igor Leonidovich Kolisnyk Oleksandr Vasyliovych Bagmut Andriy Oleksandrovich Lyashenko Anton Dmitrovich Loboda Oksana M Source Type: research
Aspirin Use Is Associated With Improved Outcomes in Inflammatory Breast Cancer Patients
CONCLUSION: ASA use during remission was associated with significantly improved OS and DMFS in patients with IBC. These results suggest that ASA may provide survival benefits to patients with IBC. Prospective clinical trials of ASA use in patients with high-risk IBC in remission should be considered.PMID:36762783 | DOI:10.4048/jbc.2023.26.e3 (Source: Journal of Breast Cancer)
Source: Journal of Breast Cancer - February 10, 2023 Category: Cancer & Oncology Authors: Christopher Johns Allen Yen Asal Rahimi Yu-Lun Liu Ann Marilyn Leitch Ann Spangler Prasanna Alluri Chika Nwachukwu Rachel Wooldridge Deborah Farr D W Nathan Kim Source Type: research
